期刊文献+

H3K27的三甲基化蛋白在初治弥漫大B细胞淋巴瘤的表达及对预后的影响 被引量:4

Expression and Prognostic Significance of H3K27 Trimethylation Protein in DLBCL
下载PDF
导出
摘要 目的:探讨H3K27me3在弥漫大B细胞淋巴瘤(DLBCL)中的表达及对预后的影响。方法:收集福建省肿瘤医院102例初治DLBCL石蜡标本,利用TMA技术制成组织芯片,免疫组织化学方法检测H3K27me3等蛋白的表达,收集临床数据和随访信息,用Kaplan-Meier法分析治疗水平,用Cox比例风险模型分析预后因素,比较不同表达与患者临床病例特征及预后关系。结果:DLBCL组织芯片位点完整。H3K27me3高表达者占59.8%,与老年(>60岁)、ECOG≥2、侵犯结外病灶数目≥2、高LDH、IPI高-中风险组相关。H3K27me3高表达组治疗完全缓解(CR)率和总有效(OR)率均低于低表达组,分别为20%vs 57.5%和41.8%vs 90%(P<0.001);高表达组中位生存时间21.5个月,较低表达组中位生存期明显缩短(P<0.0001)。COX多因素分析显示,H3K27me3高表达是DLBCL预后不良的危险因素(P=0.007)。结论:TM A技术可用于DLBCL组织芯片构建,部分DLBCL存在H3K27me3高表达。该类型患者对治疗反应差,生存期短,检测H3K27me3蛋白表达对预测DLBCL预后具有一定临床价值。 Objective:To investigate the expression and prognostic effect of H3K27 trimethylation protein(H3K27me3) in diffuse large B-cell lymphoma(DLBCL).Methods:A total of 102 DLBCL patients from Fujian Provincial Cancer Hospital were enrolled in this study.No therapy had been given before specimen collection.Tissue microarray(TMA) technique and immunohistochemistry(IHC) method were used for H3K27me3 immunostaining.Clinicopathologic and suvival data were carefully collected.The association between tested markers,clinicopathologic characteristics and prognosis were evaluated.Survival rates were analyzed by the Kaplan-Meier method,and prognostic factor were analyzed by the Cox proportional hazards model,the relation of different expression levels with clinical feature and prognosis of patients was compared.Results:The quality of TMA was perfect and meet the standard of analysis.Among all DLBCL patients,59.8%were characterized with high expression of H3K27me3,correlated with age,ECOG≥2,extranodular disease number ≥2,elevation of LDH,medium-high risk IPI.Patients with high H3K27me3 expression manifested that the complete remission rate(CR) and overall remission rate(OR) were lower than those of patients with low expression,i.e.,20%vs.57.5%and 41.8%vs.90%,respectively(P〈0.001).In addition,patients with high H3K27me3 expression showed shorter median survival time,i.e.,21.5 mon(P〈0.0001).Multivariate analysis indicated that H3K27me3 was an independent risk factor for DLBCL patients(P=0.007).Conclusion:TMA technique is valid for the construction of DLBCL tissue chips.Patients with high expression of H3K27me3 indicates little response to treatment,worse outcome and shorter overall survival.The detection of H3K27me3 expression possesses a certain clinical value for prediction of DLBCL outcome.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2016年第5期1379-1385,共7页 Journal of Experimental Hematology
基金 福建医科大学苗圃科研基金(2015MP032)
关键词 弥漫大B细胞淋巴瘤 组织芯片 H3K27me3 diffuse large B-eell lymphoma tissue microarray H3K27me3
  • 相关文献

参考文献1

二级参考文献18

  • 1Yu Jindan,Yu Jianjun,Rhodes Daniel R,Tomlins Scott A,Cao Xuhong,Chen Guoan,Mehra Rohit,Wang Xiaoju,Ghosh Debashis,Shah Rajal B,Varambally Sooryanarayana,Pienta Kenneth J,Chinnaiyan Arul M.A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Research . 2007
  • 2Eun Ji Oh,Woo Ick Yang,June-Won Cheong,Sung-eun Choi,Sun Och Yoon.Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression[J]. Human Pathology . 2014 (10)
  • 3Zhigang Xie,Wee Joo Chng,Dong Soon Lee.MMSET: Role and Therapeutic Opportunities in Multiple Myeloma[J]. BioMed Research International . 2014
  • 4William D. Bradley,Shilpi Arora,Jennifer Busby,Srividya Balasubramanian,Victor S. Gehling,Christopher G. Nasveschuk,Rishi G. Vaswani,Chih-Chi Yuan,Charlie Hatton,Feng Zhao,Kaylyn E. Williamson,Priyadarshini Iyer,Jacqui Méndez,Robert Campbell,Nico Cantone,Shivani Garapaty-Rao,James E. Audia,Andrew S. Cook,Les A. Dakin,Brian K. Albrecht,Jean-Christophe Harmange,Danette L. Daniels,Richard T. Cummings,Barbara M. Bryant,Emmanuel Normant,Patrick Trojer.EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation[J]. Chemistry & Biology . 2014 (11)
  • 5Hyun Jung Lee,Dong Hoon Shin,Kyung Bin Kim,Nari Shin,Won Young Park,Jung Hee Lee,Kyung Un Choi,Jee Yeon Kim,Chang Hun Lee,Mee Young Sol.Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone[J]. Leukemia & Lymphoma . 2014 (9)
  • 6Jianhe Chen,Jing Li,Qin Han,Zhao Sun,Jing Wang,Shihua Wang,Robert C H Zhao.Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia[J]. Experimental Biology and Medicine . 2012 (9)
  • 7Christina R. Majer,Lei Jin,Margaret Porter Scott,Sarah K. Knutson,Kevin W. Kuntz,Heike Keilhack,Jesse J. Smith,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Tim J. Wigle.A687V EZH2 is a gain-of-function mutation found in lymphoma patients[J]. FEBS Letters . 2012 (19)
  • 8Cerchietti, Leandro C,Hatzi, Katerina,Caldas-Lopes, Eloisi,Yang, Shao Ning,Figueroa, Maria E,Morin, Ryan D,Hirst, Martin,Mendez, Lourdes,Shaknovich, Rita,Cole, Philip A,Bhalla, Kapil,Gascoyne, Randy D,Marra, Marco,Chiosis, Gabriela,Melnick, Ari.BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy[J]. Journal of Clinical Investigation . 2010 (12)
  • 9Jürg Müller,Craig M. Hart,Nicole J. Francis,Marcus L. Vargas,Aditya Sengupta,Brigitte Wild,Ellen L. Miller,Michael B. O’Connor,Robert E. Kingston,Jeffrey A. Simon.Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex[J]. Cell . 2002 (2)
  • 10Morin Ryan D,Johnson Nathalie A,Severson Tesa M,Mungall Andrew J,An Jianghong,Goya Rodrigo,Paul Jessica E,Boyle Merrill,Woolcock Bruce W,Kuchenbauer Florian,Yap Damian,Humphries R Keith,Griffith Obi L,Shah Sohrab,Zhu Henry,Kimbara Michelle.Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics . 2010

共引文献11

同被引文献13

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部